Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Incidence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

2 evidence topics · 2 sources

SCN8A-related disorders: Danish birth-cohort frequency

“We found the frequency of SCN8A related disorders in the Danish population to be 1/56,247” (opens the source at this quote in a new tab)

SCN2A-related epilepsy: estimated Danish incidence, broader than DEE

“1 per 78,608 live births” (opens the source at this quote in a new tab)